# ASX ANNOUNCEMENT ECS Botanics Holdings Ltd (ASX:ECS) 4 July 2022



## ECS Exports First Shipment to New Zealand

- ECS makes the first shipment of medicinal cannabis flower to New Zealand.
- ECS supplying NUBU Pharmaceuticals New Zealand's largest distributor of medicinal cannabis products and medical devices.
- This shipment follows the successful registration of strains in New Zealand, along with Import and Export Permits granted by authorities.
- ECS strains are the first strains to be registered for import into New Zealand as dried flower for inhalation.
- Flower to be prescribed to patients under NUBU's brand KIKUYA.

**ECS Botanics Holdings Ltd (ASX: ECS) ("ECS" or the "Company")**, a leading medicinal cannabis company, is pleased to report it has concluded its first shipment of dried cannabis flower to NUBU, New Zealand's largest cannabis distributor. As previously announced ECS entered into a four-year supply agreement with Nubu (refer to ASX announcement: 30 August 2021). This shipment follows the successful registration of ECS Botanics strains, cultivated at the Company's cultivation facility in Victoria. The strains are registered as flower for inhalation, the first imported cannabis flower registered for inhalation in New Zealand.

NUBU's enviable distribution network spans the length and breadth of New Zealand – encompassing every pharmacy in the country and all major specialty clinics. The company is also the leading voice in dried flower education, to prescribers and pharmacists, via NUBU's Medical Director, Kady Chemal BPharm (Hons).

ECS anticipates that New Zealand will grow to become a strong market for ECS over the 2022/23 financial year, as the quality and competitive pricing of the Company's GMP-certified naturally, and organically grown products become increasingly in demand.

The company is currently progressing product registration in Poland and Germany.

**Managing Director of ECS, Nan-Maree Schoerie said:** "This shipment demonstrates ECS' highquality products, as New Zealand has one of the highest barriers for entry for imported medicinal cannabis. At ECS we proudly grow our cannabis naturally in soil. This ensures our flowers contain the full spectrum of primary and secondary metabolites for maximum therapeutic benefit. I am confident that our product will be as well received by New Zealand patients, as it has been by our Australian and other overseas patients."

**Co-Founder/Chief Executive Officer of NUBU, Mark Dye said:** "Having led the local market with the successful registration of dried flower for oral consumption (tea), it is great to be able to expand the portfolio of products available for New Zealand patients, with dried flower products for inhalation via ECS"

### -ENDS-

Suite 2, Level 15, 3 Spring St, Sydney NSW 2000 GPO Box 5216, Sydney NSW 2001 Cressy, TAS 7302



#### About ECS Botanics Holdings Ltd

ECS Botanics Holdings Ltd is a leading medicinal cannabis business. The company's farm and medicinal cannabis facilities are in Victoria for the cultivation, processing, and manufacturing of medicinal cannabis. ECS manufactures to EU GMP standards and also has the necessary licenses to cultivate and manufacture medicinal cannabis for the wholesale extract, final dose, and premium dry flower market. ECS' core focus is scale and low-cost production, without compromising quality.

For further information, please contact: Alexander Keach, Head of Corporate Relations info@ecs-botanics.com

#### **About NUBU Pharmaceuticals**

Formed in 2016, NUBU Pharmaceuticals (New Zealand's largest medicinal cannabis distribution company) brings medicinal cannabis products and medical devices to New Zealand, distributing them via partnerships with all the country's pharmacy networks. The company also develops New Zealand-made cannabis products for export markets, harnessing two of New Zealand's great strengths, it's innovative culture and unique botanicals.

#### www.nubupharma.com

For further information, please contact: Mark Dye, CoFounder/CEO <u>Mark.dye@nubupharma.com</u>

For further information on education, please contact: Kady Chemal, Medical Director <u>info@nubupharma.com</u>

Authorised on behalf of ECS by Alex Keach, Head of Corporate Relations